These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37943776)

  • 1. Investigating the relationship between erythropoiesis-stimulating agents and mortality in hemodialysis patients: A systematic review and meta-analysis.
    Karimi Z; Raeisi Shahraki H; Mohammadian-Hafshejani A
    PLoS One; 2023; 18(11):e0293980. PubMed ID: 37943776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of erythropoiesis-stimulating agents on systolic and diastolic blood pressure in hemodialysis patients: A systematic review and meta-analysis of clinical trials.
    Karimi Z; Raeisi Shahraki H; Mohammadian-Hafshejani A
    Med Clin (Barc); 2024 May; 162(10):e43-e51. PubMed ID: 38433073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harms of off-label erythropoiesis-stimulating agents for critically ill people.
    Mesgarpour B; Heidinger BH; Roth D; Schmitz S; Walsh CD; Herkner H
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010969. PubMed ID: 28841235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis.
    Tong Z; Xu Z; Duan Y; Sun X; Qi B
    Clin Exp Med; 2024 Jul; 24(1):150. PubMed ID: 38967734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agents and cardiovascular mortality: A systematic review and meta-analysis of 17 studies and 372,156 hemodialysis patients.
    Karimi Z; Raeisi Shahraki H; Mohammadian-Hafshejani A
    Int J Cardiol Cardiovasc Risk Prev; 2023 Dec; 19():200220. PubMed ID: 37953767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis.
    Marchetti C; De Felice F; Palaia I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
    Crit Rev Oncol Hematol; 2016 Mar; 99():123-8. PubMed ID: 26748593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials.
    Kang J; Park J; Lee JM; Park JJ; Choi DJ
    Int J Cardiol; 2016 Sep; 218():12-22. PubMed ID: 27209352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
    Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
    Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
    Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten years of meta-analyses on erythropoiesis-stimulating agents in cancer patients.
    Tonia T; Bohlius J
    Cancer Treat Res; 2011; 157():217-38. PubMed ID: 21052959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of erythropoiesis-stimulating agents on breast cancer patients: a meta-analysis.
    Wu T; Tong Z; Ren T; Xie D; Sun X
    Clin Exp Med; 2023 Sep; 23(5):1501-1513. PubMed ID: 36315312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis.
    Gao S; Ma JJ; Lu C
    Tumour Biol; 2014 Jan; 35(1):603-13. PubMed ID: 23959477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
    Aapro M; Spivak JL
    Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.
    Amato L; Addis A; Saulle R; Trotta F; Mitrova Z; Davoli M
    J Nephrol; 2018 Jun; 31(3):321-332. PubMed ID: 28646375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
    Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
    Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin or darbepoetin for patients with cancer.
    Tonia T; Mettler A; Robert N; Schwarzer G; Seidenfeld J; Weingart O; Hyde C; Engert A; Bohlius J
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003407. PubMed ID: 23235597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
    Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
    Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.